What is the Hypothalamus-pituitary-adrenal (HPA) axis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

The Hypothalamus-Pituitary-Adrenal (HPA) Axis

Overview and Core Function

The HPA axis is a neuroendocrine system that mediates the body's stress response through a cascade of hormonal signals originating in the hypothalamus, transmitted through the pituitary gland, and culminating in cortisol release from the adrenal glands. 1

The HPA axis represents one of the main components of the stress system and is essential for maintaining physiological homeostasis in response to internal or external stimuli. 2 This system integrates with the sympathetic branch of the autonomic nervous system and the host immune system to coordinate the organism's response to external stressors. 1

Anatomical and Hormonal Cascade

The Three-Tier Hormonal Sequence

The hypothalamus initiates the cascade: Paraventricular nucleus neurons in the hypothalamus release corticotropin-releasing factor (CRF), also called corticotropin-releasing hormone (CRH). 1

The pituitary amplifies the signal: CRF stimulates the anterior pituitary gland to secrete adrenocorticotropin hormone (ACTH) into the circulation. 1

The adrenal glands produce the effector hormone: ACTH acts on the adrenal cortex (not the adrenal medulla as sometimes stated), resulting in cortisol secretion into the bloodstream. 1 Cortisol and other glucocorticoids are the final effectors of the HPA axis and regulate a broad spectrum of physiologic functions essential for life through their ubiquitously distributed intracellular receptors. 3

Regulatory Control Mechanisms

Feedback Loops

The production and release of CRF operates under multiple control systems, reflecting the pluripotent role of this peptide in controlling autonomic, immunological, and emotional responses to stress. 1

Input regulation: CRF release depends on input from limbic structures in the brain and from peripheral feedback by ACTH and cortisol levels. 1 This creates a negative feedback system that prevents excessive activation under normal circumstances.

Assessment considerations: Circulating peripheral levels of CRF do not reflect levels released into the hypophyseal portal circulation, so HPA axis activity is traditionally assessed by measuring ACTH and cortisol rather than CRF itself. 1

Physiological Roles

Stress Response

The HPA axis functions as the final common pathway in the stress response, with activation proportional to the intensity of emotional and systemic stressors. 1, 4 The system is extremely sensitive and can be triggered by a wide range of psychological experiences and physiological perturbations. 4

Homeostatic Maintenance

Maintenance of normal physiological events depends on appropriate HPA axis function, and sufficient cortisol levels in circulation are essential for survival. 2 The axis plays an important role in maintaining both basal and stress-related homeostasis. 3

Metabolic and Immune Integration

The HPA axis coordinates with the immune system, with abnormal functioning inducing release of multiple hormones including cortisol, pro-inflammatory cytokines, and glucocorticoids. 1 Chronic activation leads to pro-inflammatory cytokine elevation (IL-1β, IL-6, TNF-α), contributing to depression and anxiety disorders. 5

Pathophysiology and Clinical Significance

Chronic Stress Effects

Chronic stress leads to persistent HPA axis activation that differs significantly from the adaptive response seen in acute stress. 5 This results in:

  • Insulin resistance and compensatory hyperinsulinemia, predisposing to hyperglycemia and diabetes 5
  • Reduced hippocampal and medial prefrontal cortex volume and functionality 5
  • Decreased hippocampal neurogenesis and dendritic retraction 5
  • Metabolic remodeling with disturbed energy production and tendency toward ketosis 5

Disease States

HPA axis dysregulation manifests in multiple clinical conditions:

  • Altered HPA axis activity is one of the most commonly observed neuroendocrine abnormalities in patients with depressive disorder 1
  • Hyperthyroidism precipitates anxiety through cross-communication between the central thyroid system and HPA-related noradrenergic and serotonergic pathways 6
  • Pheochromocytomas cause anxiety through massive catecholamine release that activates the "fight or flight" response, with anxiety attacks occurring as direct manifestations of catecholamine surges 6, 7
  • Myocardial infarction precipitates anxiety through direct neurohormonal activation from cardiac injury and ongoing autonomic dysregulation 6

Adrenal Insufficiency

In severe cortisol deficiency, especially with a triggering factor, patients may develop life-threatening adrenal crisis resulting in death unless early diagnosis and adequate treatment occur. 2 Life-long glucocorticoid replacement therapy meeting but not exceeding patient needs is essential for normal life expectancy and quality of life. 2

Clinical Assessment

Diagnostic Approach

For frank manifestations: Basal cortisol is usually sufficient for diagnosis without requiring dynamic testing. 2

For secondary adrenal insufficiency in the "gray zone": More complicated methods that simulate the HPA axis response to major stress are required when clinical manifestations are mild. 2

Standard screening tests include:

  • 1 mg dexamethasone suppression test for autonomous cortisol secretion 7
  • Plasma free metanephrines or 24-hour urinary metanephrines for suspected pheochromocytoma 7
  • Classical endocrinological challenges (CRF administration, ACTH administration, or dexamethasone) to evaluate tonic changes in the axis 4

Important Diagnostic Pitfalls

Pheochromocytomas can be misdiagnosed as primary anxiety disorders, leading to dangerous delays in treatment. 7 Some adrenal nodules may cause subclinical hormone excess contributing to anxiety symptoms that might be missed on routine testing. 7 Imaging characteristics alone cannot reliably distinguish between benign and malignant adrenal masses or functional versus non-functional tumors. 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The hypothalamic-pituitary-adrenal axis: what can it tell us about stressors?

CNS & neurological disorders drug targets, 2006

Guideline

Hormonal Characteristics of Chronic Stress

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pathophysiological Mechanisms of Anxiety in Hyperthyroidism, Myocardial Infarction, and Pheochromocytoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Adrenal Nodules and Anxiety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.